Alliance Global Partners initiated coverage of Journey Medical with a Buy rating and $8.50 price target. Journey’s base dermatology business combined with its pipeline drug DFD-29 can drive revenue growth and ultimately profits to the company, the analyst tells investors in a research note. The firm says the company has a strong base of dermatology products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DERM:
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
- Journey Medical submits NDA to FDA for DFD-29
- Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
- Journey Medical Corp trading resumes
- Journey Medical Corp trading halted, volatility trading pause
